LUOTAI group treated with LUOTAI with dosage, dosing schedule and duration follows local clinical practice in accordance with the terms of the local marketing authorization: 400mg of LUOTAI injectable lyophilized powder diluted in 250ml of 5% Glucose Solution or 0.9% Normal Saline for included diabetic patients, via slow intravenous infusion, once daily for consecutive 14 days, and followed by 200mg of LUOTAI soft capsules, three times a day for 65 days.

Control group comprises of patients who are not treated with LUOTAI, and follows local clinical practice for ischemic stroke.

Infarction, Anterior Cerebral Artery

Infarction, Middle Cerebral Artery

Ischemic Attack, Transient

Bach Mai Hospital

Phu Tho General Hospital

103 Military Hospital

An Observational Registry Study of LUOTAI in Patients With Acute Ischemic Stroke in Vietnam

A Non-interventional, Controlled, Open-label, Observational Registry Study to Investigate the Safety and Effectiveness of LUOTAI (Panax Notoginseng) Injectable and Soft Capsules in Patients With Acute Ischemic Stroke in Vietnam

Modified Rankin Scale (mRS) is an overall functional outcome measure, measuring stroke defect. Answer the test questions for 5-10 minutes. The score range is 7 points with a score of 0 for the absence of sequelae and the worst possible score is 6.
0 - No symptoms.
- No significant disability. Able to carry out all usual activities, despite some symptoms.
- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.
- Moderate disability. Requires some help, but able to walk unassisted.
- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.
- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.
- Dead. Primary Efficacy Endpoint defined as "Categorical shift in mRS score at 3 months (ordinal logistic regression analysis of the mRS on Day 90)".

Ordinal NIHSS at 3 months after stroke onset

Ordinal MoCA at 3 months after stroke onset

Proportion of patients with excellent recovery and functional dependence at 3 months after stroke onset (mRC=0 or 1)

KPC Pharmaceuticals, Inc

Comply to the Chinese guidlines of acute ischemic stroke in 2014

Treat with KDZ injection on the basis of basic treatment

Treat with Xueshuantong injection on the basis of basic treatment

Treat with both KDZ injection and Xueshuantong injection on the basis of basic treatment

Ischemic Stroke

KDZ40ml+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.

Ixeris of sonchifolia Hance

Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.

Panax notoginseng saponins

KDZ40ml+0.9%N.S.250ml,ivdrip;Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.

Ixeris of sonchifolia Hance combined with Panax notoginseng saponins

Department of Neurology,Dongfang Hospital

Department of Neurology,Huairou Hospital of Traditional Chinese Medicine

Department of Neurology,Affiliated Hospital of Shandong University of Traditional Chinese Medicine

Department of Neurology,Wuqing Hospital of Traditional Chinese Medicine

Heat-clearing and Blood-activating Chinese Medicinal Components in Acute Cerebral Infarction

Heat-clearing and Blood-activating Chinese Medicinal Components in Acute Cerebral Infarction: Mechanisms of Multi-target Anti-inflammatory Action

Yunling Zhang

President of Dongfang Hospital

Shandong University of Traditional Chinese Medicine

Huairou Hospital of Traditional Chinese Medicine

Placebo 1.2 g per day for 12 weeks, followed by a second treatment period with aged garlic extract during 12 more weeks.

Aged garlic extract, 1.2 g per day for 12 weeks, followed by a second treatment period with placebo during 12 more weeks.

Metabolic Syndrome

Aged garlic extract, 1.2 g per day for 12 weeks

aged garlic extract

Placebo

Medicine School, Universidad de Santander

Trial of Supplementation With Aged Garlic Extract to Improve Endothelial Function in Patients With Metabolic Syndrome

A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE SUPPLEMENTATION WITH KIOLIC® IN PATIENTS WITH DIAGNOSIS OF METABOLIC SYNDROME TO IMPROVE ENDOTHELIAL FUNCTION AND INFLAMMATORY STATE. "KYMES"

The flow mediated vasodilation is a non-invasive diagnostic test using high-resolution doppler ultrasound, that measures the changes in diameter of the brachial artery in response to increased blood flow (reactive hyperemia).
The plasma levels of nitrites/nitrates will be determined by immunoassay (R&D Systems, Inc)

During the initial and follow-up visits, a blood sample will be taken to determine C-reactive protein by high sensitivity chemiluminescent immunometric assay (IMMULITE 1000, DPC, Los Angeles, CA) and Interleukin-6 by immunoassay (Biosource International, Camarillo, CA)

Blood samples will be taken at the initial and follow-up visits (12,24 weeks) to determine blood glucose by automatic colorimetric method (Baker System 9120 AX, Biochem Immunosystem, Allentown, PA)and insulin plasma levels by high sensitivity chemiluminescent immunometric assay (IMMULITE 1000, DPC, Los Angeles, CA).

Anthropometric measures will be determined at the initial and follow-up visits (12,24 weeks).

Blood samples will be taken at the initial and follow-up visits (12,24 weeks) to determine adiponectin by Human Adiponectin/Acrp30 Quantikine ELISA (R&D Systems, USA)

Patricio López-Jaramillo

Universidad de Santander

Instituto de Salud de Bucaramanga

both a ginsenoside-Rd injection (10mg/1ml/each) and a specific dilution (10%, 1ml trimethylene glycol) were respectively diluted by a specific dilution (10%, 9 ml trimethylene glycol) and then mixed.

2 specific dilutions (10%, 1ml trimethylene glycol) were respectively diluted by 2 specific dilutions (10%, 9 ml trimethylene glycol) and then mixed.

2 ginsenoside-Rd injections (10mg/1ml/each) were respectively diluted by 2 specific dilutions (10%, 9 ml trimethylene glycol) and then mixed

infusion ginsenoside-Rd 10 mg (group A)once a day and continued for 14 days

ginsenoside-Rd 10 mg

infusion placebo (group B)once a day and continued for 14 days

placebo

infusion of ginsenoside-Rd 20mg (group C) once a day and continued for 14 days

saponin/infarkt

An Observational Registry Study of LUOTAI in Patients With Acute Ischemic Stroke in Vietnam

Heat-clearing and Blood-activating Chinese Medicinal Components in Acute Cerebral Infarction

Trial of Supplementation With Aged Garlic Extract to Improve Endothelial Function in Patients With Metabolic Syndrome

Ginsenoside-Rd for Acute Ischemic Stroke

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen